We are live on ! Find out more
AC

Aisling Capital Portfolio holdings

AUM $45.3M
1-Year Est. Return 15.24%
This Fund
S&P 500
This Quarter Est. Return
+4.64%
1 Year Est. Return
-15.24%
3 Year Est. Return
+386.13%
5 Year Est. Return
+981.36%
10 Year Est. Return
–
AUM
$346M
AUM Growth
+$202M
Cap. Flow
+$189M
Cap. Flow %
54.74%
Top 10 Hldgs %
93.11%
Holding
17
New
12
Increased
2
Reduced
1
Closed
1

Top Buys

Rank Stock Value
1
ARAV
Aravive, Inc. Common Stock
ARAV
+$57.4M
2
ZLTQ
ZELTIQ Aesthetics, Inc.
ZLTQ
+$44.4M
3
ASXC
Asensus Surgical, Inc.
ASXC
+$37M
4
CEMP
Cempra, Inc.
CEMP
+$31.8M
5
ESPR
Esperion Therapeutics
ESPR
+$29.7M

Top Sells

Rank Stock Value
1
IQV icon
IQVIA
IQV
+$58.6M
2
DRTX
DURATA THERAPEUTICS INC COM STK (DE)
DRTX
+$14.9M

Sector Composition

Rank Sector Weight
1 Healthcare 75.61%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARAV
1
DELISTED
Aravive, Inc. Common Stock
ARAV
$55.9M 16.17%
+332,428
New +$57.4M
ASXC
2
DELISTED
Asensus Surgical, Inc.
ASXC
$42M 12.14%
+641,217
New +$37M
ZLTQ
3
DELISTED
ZELTIQ Aesthetics, Inc.
ZLTQ
$39.5M 11.41%
+2,597,742
New +$44.4M
CEMP
4
DELISTED
Cempra, Inc.
CEMP
$35.3M 10.21%
+3,293,060
New +$31.8M
DRTX
5
DELISTED
DURATA THERAPEUTICS INC COM STK (DE)
DRTX
$34.6M 9.99%
2,030,175
-1,000,000
-33% -$14.9M
CMRX
6
DELISTED
Chimerix, Inc.
CMRX
$33.4M 9.66%
1,522,943
+300,000
+25% +$5.96M
ESPR
7
DELISTED
Esperion Therapeutics
ESPR
$32.5M 9.41%
+2,054,594
New +$29.7M
AGRX
8
DELISTED
Agile Therapeutics
AGRX
$18.9M 5.47%
+1,086
New +$15.7M
PTX
9
DELISTED
Pernix Therapeutics Holdings, Inc.
PTX
$18.1M 5.22%
+201,000
New +$12.3M
SRNE
10
DELISTED
Sorrento Therapeutics, Inc.
SRNE
$11.9M 3.44%
1,763,500
+1,142,800
+184% +$8.62M
AMBI
11
DELISTED
Ambit Biosciences Corp
AMBI
$11.4M 3.3%
+1,650,156
New +$11.6M
EVAR
12
DELISTED
Lombard Medical, Inc.
EVAR
$6.38M 1.84%
+886,363
New +$7.22M
LITS
13
Lite Strategy Inc
LITS
$35M
$4.88M 1.41%
38,500
– –
ZLTQ
14
CALL
DELISTED
ZELTIQ Aesthetics, Inc.
ZLTQ
$657K 0.19%
+43,261
New +$739K
CEMP
15
CALL
DELISTED
Cempra, Inc.
CEMP
$429K 0.12%
+40,000
New +$386K
PTX
16
CALL
DELISTED
Pernix Therapeutics Holdings, Inc.
PTX
$90K 0.03%
+1,000
New +$61.3K
IQV icon
17
IQVIA
IQV
$34B
– –
-1,153,773
Closed -$58.6M

Similar funds

SCPM
Sagard Capital Partners Management New York $46.7M AUM 23.43% 1-Year Est. Return
ZIM
ZPR Investment Management Orange City, Florida $46.8M AUM 2.45% 1-Year Est. Return
ACP
Aquiline Capital Partners New York $46.9M AUM 5.65% 1-Year Est. Return
INL
IPC/NYCG LLC New York $43.3M AUM 61.41% 1-Year Est. Return
CP
Clover Partners Dallas, Texas $43.1M AUM 4.09% 1-Year Est. Return
SAM
Sheffield Asset Management Chicago, Illinois $48.1M AUM 12.96% 1-Year Est. Return
JCM
Julex Capital Management Wellesley, Massachusetts $42.4M AUM 9.78% 1-Year Est. Return
GX
Greylock XII Menlo Park, California $51.9M AUM 11.52% 1-Year Est. Return

Aisling Capital's Q2 2014 Portfolio in Review

As of Q2 2014, Aisling Capital held 17 positions worth $346M, up 140% from $144M the previous quarter. Its ten largest holdings account for 93% of the portfolio.

Aisling Capital deployed $189M of net new capital in Q2 2014, opening 12 new positions and adding to 2 existing holdings. Its largest new stake was Aravive, Inc. Common Stock: 332,428 shares worth $55.9M.

By sector, the portfolio is most concentrated in Healthcare at 76% of assets, up from 66% a quarter earlier.

On the sell side, the largest reduction was DURATA THERAPEUTICS INC COM STK (DE), an estimated $14.9M trimmed.

  • Aisling Capital's largest Q2 2014 buy was Aravive, Inc. Common Stock: 332,428 shares worth $55.9M.
  • Aisling Capital added most to Sorrento Therapeutics, Inc. in Q2 2014, an estimated $8.62M increase.
  • Aisling Capital's biggest Q2 2014 reduction was DURATA THERAPEUTICS INC COM STK (DE), cutting an estimated $14.9M.
  • Aisling Capital fully exited IQVIA in Q2 2014, selling an estimated $58.6M.
  • Aisling Capital's ten largest holdings make up 93% of its $346M portfolio in Q2 2014.
  • Aisling Capital opened 12 new positions and closed 1 in Q2 2014.
  • Aisling Capital's portfolio value rose 140% quarter-over-quarter to $346M.

Based on Aisling Capital's 13F filing for Q2 2014, filed 8 Aug 2014.